Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital
GlobeNewswire - Wed Jul 06, 7:08AM CDT
Apricus Biosciences, Inc. (Nasdaq:APRI) (the "Company" or "Apricus"
APRI: 0.38 (-0.01)
The Medicines Co.'s Carbavance Scores in Phase III Study
Arpita Dutt - Zacks Investment Research - Tue Jun 28, 9:45AM CDT
The Medicines Co. (MDCO) intends to file for FDA approval in early 2017.
MDCO: 36.51 (+1.61), ANIP: 55.83 (-0.68), ARQL: 1.72 (-0.02), APRI: 0.38 (-0.01)
Biocom Appoints New Directors to its Board
PR Newswire - Tue Jun 07, 11:01AM CDT
Biocom, the association representing the Southern California life science community, today announced the appointment of 13 new directors to its board, including the appointment of Charles Dadswell, senior vice president and general counsel for Illumina, and Rich Pascoe, chief executive officer of Apricus Biosciences, to the executive committee of Biocom's board. In addition, Biocom announced that Magda Marquet, Ph.D., co-founder of Ajinomoto Althea and AltheaDx, and Brent D. Jacobs, executive director in the global life sciences practice group at Cushman & Wakefield, were named as life directors, a prestigious and special class of director.
APRI: 0.38 (-0.01)
ARIAD (ARIA) Commences Phase I/II Study on Cancer Drug
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 4:05PM CDT
ARIAD (ARIA) announced the initiation of a phase I/IIstudy on AP32788 for the treatment of non-small cell lung cancer with specific mutations in EGFR or HER2.
APRI: 0.38 (-0.01), JNP: 7.64 (-0.25), ARIA: 7.43 (-0.08)
Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 41.00 (-0.69), ARQL: 1.72 (-0.02), APRI: 0.38 (-0.01), RPRX: 1.73 (unch)
Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed May 11, 7:10AM CDT
Jazz (JAZZ) raised its earnings outlook for the year based on a lower share count.
BSTC: 41.00 (-0.69), JAZZ: 141.04 (+1.16), ARQL: 1.72 (-0.02), APRI: 0.38 (-0.01)
Apricus reports 1Q loss
Automated Insights - Mon May 09, 6:49AM CDT
SAN DIEGO (AP) _ Apricus Biosciences Inc. (APRI) on Monday reported a loss of $2.5 million in its first quarter.
APRI: 0.38 (-0.01)
Apricus Biosciences Provides Corporate Update and First Quarter Financial Results
Globe Newswire - Mon May 09, 6:00AM CDT
Vitaros(R) U.S. NDA Re-Submission on Schedule for 3Q 2016
APRI: 0.38 (-0.01)
CORRECTING and REPLACING -- Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros(R) and Erectile Dysfunction Population
Globe Newswire - Tue May 03, 1:44PM CDT
In a release issued under the same headline earlier today by Apricus Biosciences, Inc. (Nasdaq:APRI), please note that in the second line of the subhead of the release, "2H 2016" should instead be "Q3 2016."
APRI: 0.38 (-0.01)
Apricus Biosciences to Host Live Webcast KOL Event on May 9th Addressing Vitaros(R) and Erectile Dysfunction Population
Globe Newswire - Tue May 03, 6:01AM CDT
Presentation Speaker will be Edward D. Kim, M.D., Professor, The University of Tennessee Graduate School of Medicine
APRI: 0.38 (-0.01)
Apricus Biosciences to Announce Corporate Update and First Quarter 2016 Financial Results
Globe Newswire - Tue May 03, 6:00AM CDT
SAN DIEGO, May 03, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the Company's first quarter 2016 financial results will be released on Monday, May 9, 2016 at 7:00 a.m. Eastern Time.
APRI: 0.38 (-0.01)
New Strong Buy Stocks for April 26th
Zacks Equity Research - Zacks Investment Research - Tue Apr 26, 7:40AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
AXE: 55.04 (+0.28), ANIP: 55.83 (-0.68), APRI: 0.38 (-0.01), ALQA: 1.17 (-0.02), FLWS: 9.64 (+0.50)
Raynauds Disease - Pipeline Review, H1 2016 Featuring Allergan, Apricus Biosciences, Bayer, Covis Pharmaceuticals & Human Stem Cells Institute - Research and Markets
BusinessWire - Tue Apr 19, 10:26AM CDT
Research and Markets has announced the addition of the "Raynauds Disease - Pipeline Review, H1 2016" report to their offering.
AGN: 240.70 (+0.11), APRI: 0.38 (-0.01)